Healthy Skepticism Library item: 6585

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Vitry A.
Re: the promotion of Coversyl (perindopril)
MaLAM Australian News 1995 May;

Abstract:

Servier claims that Coversyl (perindopril) remodels hypertensive arteries and controls blood pressure for 24 hours after a single dose. There is no clinical evidence that Coversyl provides any better blood pressure control than other long-acting ACE inhibitors. The benefits of arterial remodeling have not been shown to be clinically relevant. The safety of Coversyl in certain populations is also questionable.

Keywords:
*analysis/Australia/developed countries/Coversyl/perindopril/Servier/quality of information/safety & risk information/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DRUG SAFETY/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES